ArticlePharmacoEconomics2026
Comparison of Alternative Outcome Measures in Cost-Effectiveness Analysis: Three Applications Within Oncology.
Article in PharmacoEconomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundQuality-adjusted life-years (QALYs) are the predominant health benefit measure used in health technology assessment. In response to legal and policy constraints on the use of QALYs in some jurisdictions, alternative outcome measures, such as equal value life-years and health years in total, have been proposed. However, there is limited illustration of how these alternative measures behave when applied to common health economic model structures.
methodsThree stylized oncology economic models, reflecting typical features of published cost-effectiveness analyses, were used to examine how alternative outcome measures re-express identical underlying survival and health-related quality-of-life inputs. Outcomes based on QALYs were compared with those based on life-years, equal value life-years, and health years in total for renal cell carcinoma, chronic myeloid leukemia, and non-small cell lung cancer.
resultsIncremental health years in total were consistently larger than incremental QALYs (13-46% higher). The relationship between life-years and QALYs varied across indications (from 63% lower to 43% higher).
conclusionsWhen applied to identical model inputs, alternative outcome measures primarily re-express existing information rather than incorporate additional dimensions of health benefit. Differences relative to QALYs reflect alternative weighting of survival and health-related quality-of-life effects and depend on the balance between these components. These findings highlight the need for careful interpretation of alternative measures when used alongside QALYs in economic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.